The Healthcare Stage

The Healthcare Stage I Episode 12 I Accellta's Journey: Innovating Stem Cells for FoodTech

In this episode, we explore the journey of Accellta, an Israeli company founded 12 years ago with a mission to revolutionize the cultivation and manufacturing of stem cells. Stem cells, known for their ability to differentiate into various specialized cell types and undergo unlimited cell divisions, hold immense potential in the biotech and food-tech industries. Accellta's proprietary 3D suspension culture platform addresses the critical scalability bottleneck in stem cell production, enabling large-scale, cost-effective manufacturing. Their innovative approach ensures affordable end-products, including chemically defined media and proprietary stable cell lines derived from humans, aquatic animals, and farm animals. Since 2018, Accellta has achieved stable profitability through its diverse services and partnerships with global industry leaders.  Now, the company seeks $5 million to scale up its capabilities for the evolving food tech industry. If you are an investor looking for new opportunities in the food tech space, this podcast is for you.

The Healthcare Stage I Episode 11 I MDI's Novel Solution for Optimizing Health Outcomes & Reducing Costs in Polypharmacy Patients

In this episode, we sit down with Avishai Ben Tovim, CEO of MDI, a company founded in 2019. MDI has developed a groundbreaking risk analysis system for polypharmacy patients, designed to manage complex cases and provide accurate clinical recommendations for treatment optimization and risk mitigation. Despite increasing efforts to prevent adverse drug reactions over the past decade, drug-induced hospitalizations and mortality rates continue to rise. MDI's medication management platform addresses this issue by scaling up the prevention process, helping physicians and payors avoid the clinical and financial consequences of drug-related adverse events. The platform conducts comprehensive drug-related risk analyses for entire populations, identifying at-risk individuals and providing financial projections even before conducting per-patient analyses. By analyzing thousands of pharmacological and medical parameters, MDI's algorithms enable payors and physicians to pinpoint precise and immediate health risks, generating evidence-based clinical recommendations to reduce these risks. MDI's mission is to enable Value Based Care, focusing on clinical quality and cost reduction. Join us as we discuss MDI's innovative solution, the validation they generated, , and their future goals. 🎧 This Podcast is also available in a video format on “The Healthcare Stage” YouTube channel

The Healthcare Stage I Episode 10 I A novel navigation system for ERCP procedure by Swift Duct

In this episode, we delve into the groundbreaking innovations of Swift Duct, an Israeli medical device company founded in 2020, with CEO Samer Abboud. Swift Duct is on a mission to transform Endoscopic retrograde cholangio-pancreatography (ERCP), a vital procedure aimed at and treating detecting biliary and pancreatic duct blockages. Through a captivating discussion, we discuss how Swift Duct's cutting-edge navigation solution aims to revolutionize ERCP, promising easier, faster, and safer procedures. With a catheter boasting unique bending capabilities and a sensor-equipped guidewire, the company aims to streamline the process, reduce trial and error, and ultimately mitigate healthcare costs and patient suffering. We discuss Swift Duct's journey from seed funding to successfully demonstrating their technology's proof of concept in preclinical trials. Join us to explore how Swift Duct's innovative approach stands to benefit over 2 million ERCP procedures annually and why this venture presents a compelling investment opportunity in the MedTech landscape. If you're an investor seeking new prospects in the MedTech sector, tune in to gain insights into the potential future of ERCP and the promising advancements brought forth by Swift Duct. Listen now on Spotify and Apple Podcast or view on “the Healthcare Stage" YouTuve channel, and stay ahead in the ever-evolving world of MedTech! 🚀 #TheHealthcareStage #MedTech #HealthcareInnovation  #ERCP #VC #Investment #Startup #SwiftDuct

The Healthcare Stage I Episode 9 I Pulsar Medtech's breakthrough bone growth stimulation device for fresh fractures treatment.

In this episode, we delve into a fascinating conversation with Elad Yakobson, the CEO of Pulsar Medtech, an Israeli startup making waves in the MedTech industry. Tune in to discover how Pulsar Medtech is revolutionizing bone healing with its innovative Bone Growth Stimulation devices. Pulsar Medtech's devices offer a promising solution to enhance patient comfort and compliance, addressing challenges commonly faced with existing bone growth stimulation devices. With lightweight patches designed for improved comfort and adherence, Pulsar Medtech is paving the way for better clinical outcomes. Discover the safety and efficacy of Pulsar Medtech's devices, backed by rigorous clinical studies. Find out how they're gearing up for a pivotal study in the US in 2024 and their plans to raise $6-8 million to facilitate FDA approval and market penetration. For investors seeking opportunities in the MedTech space, this podcast provides valuable insights into Pulsar Medtech's innovative approach and future prospects. Listen now on Spotify and Apple Podcast or view on "The Healthcare Stage" YouTube channel, and stay ahead in the ever-evolving world of MedTech! 🚀 #TheHealthcareStage #MedTech #HealthcareInnovation #BoneHealing #Bonegrowthstimulation #Fractures #orthopedicpatients #VC #Investment #Startup #PulsarMedtech

The Healthcare Stage I Episode 8 I Golden Heart Flower's GHF201: Advancing Rare Disease Treatment

This episode is dedicated to a conversation with Yaniv Glazer, The CEO of Golden Heart Flower, an early-stage Israeli pharmaceutical company dedicated to addressing rare diseases. Specifically, we explore their focus on Adult Polyglucosan Body Disease (APBD) and their development of GHF201, a small molecule drug. GHF201 shows promise beyond APBD, potentially impacting various lysosomal storage diseases by enhancing lysosomal activity. With approval for compassionate use from the Israeli Ministry of Health, the company has gathered 5 years of clinical data from 3 APBD patients, indicating both safety and efficacy. Currently seeking $10M in funding to complete CMC and toxicology studies, Golden Heart Flower aims to initiate its first clinical study. For pharmaceutical investors interested in the rare disease sector, this podcast offers a sober analysis of the company's progress and investment prospects.